Published: Jan. 1, 2024
Language: Английский
EP Europace, Journal Year: 2024, Volume and Issue: 26(9)
Published: July 30, 2024
Abstract Aims The concept of “atrial cardiomyopathy” (AtCM) had been percolating through the literature since its first mention in 1972. Since then, publications using term were sporadic until decision was made to convene an expert working group with representation from four multinational arrhythmia organizations prepare a consensus document on atrial cardiomyopathy 2016 (EHRA/HRS/APHRS/SOLAECE cardiomyopathies: definition, characterization, and clinical implication). Subsequently, AtCM have increased progressively. Methods results present elaborates further implement simple staging system (AtCM stages 1–3) by integrating biomarkers, geometry, electrophysiological changes. However, proposed needs validation. Importantly, it is clearly stated that presence might serve as substrate for development fibrillation (AF) AF may accelerates substantially, but per se be viewed separate entity. Conclusion Thus, serves statement European Heart Rhythm Association (EHRA) ESC, Society (HRS), Asian Pacific (APHRS), Latin American (LAHRS) contribute evolution concept.
Language: Английский
Citations
49
Journal of Molecular and Cellular Cardiology, Journal Year: 2025, Volume and Issue: 202, P. 13 - 23
Published: March 6, 2025
Inflammasomes are multiprotein complexes of the innate immune system that mediate inflammatory responses to infection and local systemic stress tissue injury. The principal function is facilitate caspase-1 auto-activation subsequently maturation release effectors interleukin (IL)-1β IL-18. atrial-specific NLRP3 inflammasome a unifying causal feature atrial fibrillation (AF) development, progression recurrence after ablation. Many AF-associated risk factors co-morbidities converge mechanistically on activation this central signaling platform. This review presents historical conceptual development distinct its potential involvement in AF. We follow early observations linking inflammation with AF, emergence an atrial-intrinsic operating within not just cells but also resident fibroblasts cardiomyocytes. outline key developments understanding how effector IL-1β contribute causally cellular tissue-level arrhythmogenesis different pathological settings, candidate therapeutic concepts verified preclinical models cardiomyopathy
Language: Английский
Citations
0
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 3250 - 3250
Published: May 7, 2025
Atrial fibrillation (AF) is increasingly recognized not merely as an arrhythmia, but a clinical manifestation of atrial cardiomyopathy (AtCM)—a progressive, multifaceted disease the myocardium involving structural, electrical, mechanical, and molecular remodeling. AtCM often precedes AF onset, sustains its perpetuation, contributes to thromboembolic risk independently rhythm status. Emerging evidence implicates diverse pathophysiological drivers AtCM, including inflammation, epicardial adipose tissue, metabolic dysfunction, oxidative stress, ageing, sex-specific The NLRP3 inflammasome has emerged central effector in inflammation Gut microbial dysbiosis, lipid dicarbonyl fibro-fatty infiltration are also contributors arrhythmogenesis. further linked functional valve regurgitation adverse outcomes AF. Therapeutically, substrate-directed strategies—ranging from modulation immunomodulation early control—offer promise for altering trajectory. This review synthesizes mechanistic insights into discusses emerging therapeutic paradigms that aim suppress arrhythmia modify underlying substrate. Recognizing syndrome reframes management strategies highlights urgent need precision medicine approaches targeting
Language: Английский
Citations
0
Published: Jan. 1, 2024
Language: Английский
Citations
0